Mitochondrial Peptides Humanin and MOTS-c Could Slow Vascular Aging
A new review maps how mitochondria-derived peptides protect blood vessels, reduce oxidative stress, and signal through AMPK, mTOR, and sirtuin pathways.
Summary
As we age, blood vessels stiffen, become inflamed, and lose their ability to regulate blood flow — largely due to failing mitochondria. This review examines a newly recognized family of peptides encoded directly within mitochondrial DNA: humanin, MOTS-c, and small humanin-like peptides (SHLP1–6). These molecules circulate in the bloodstream, decline with age, and act like hormones to protect endothelial cells, reduce oxidative stress, suppress inflammatory signaling, and activate longevity-linked pathways including AMPK, mTOR inhibition, and SIRT1. The authors argue these peptides are compelling dual-purpose candidates — both as early biomarkers of vascular aging risk and as potential therapeutic agents targeting the core biology of age-related cardiovascular disease.
Detailed Summary
Vascular aging — the progressive stiffening, remodeling, and functional decline of arteries — is among the most powerful predictors of cardiovascular disease and mortality in older adults. At its root lies mitochondrial dysfunction: as mitochondria deteriorate with age, they overproduce reactive oxygen species (ROS), leak mitochondrial DNA, impair nitric oxide (NO) bioavailability, and trigger chronic low-grade inflammation through mechanisms including the senescence-associated secretory phenotype (SASP). This review, published in Current Cardiology Reviews, synthesizes evidence from PubMed, Scopus, and Google Scholar covering studies from 2000 to 2024 on a family of endogenous mitochondrial-derived peptides (MDPs) and their relevance to vascular aging and cardiovascular disease.
Humanin, MOTS-c, and the six small humanin-like peptides (SHLP1–6) are bioactive microproteins encoded by short open reading frames within mitochondrial DNA — a previously underappreciated coding reservoir. These peptides are released into circulation via non-classical secretion and through extracellular vesicles including exosomes, enabling them to act as systemic endocrine-like signals. Critically, circulating levels of both humanin and MOTS-c decline measurably with aging, paralleling the deterioration of vascular function. Exercise is noted to upregulate humanin levels in athletes, suggesting lifestyle interventions can modulate these peptides.
The signaling mechanisms are well-characterized. MOTS-c activates AMPK — the master cellular energy sensor — which mimics the metabolic effects of exercise, improves insulin sensitivity, and promotes metabolic homeostasis. In coronary artery disease patients, lower serum MOTS-c levels correlate with greater CAD severity, and in obese individuals, reduced MOTS-c associates with impaired reactive hyperemia index (RHI), a direct measure of endothelial function. Humanin activates cytoprotective cascades and indirectly modulates mTOR, the central nutrient-sensing regulator of cellular aging, while SIRT1 activation by MDPs reduces oxidative stress markers and suppresses hyperglycemia-induced endothelial senescence. In diabetic cardiomyopathy models, MOTS-c attenuates apoptosis and promotes angiogenesis, pointing toward therapeutic utility in high-risk metabolic disease populations.
The review highlights an important cell-type specificity: in endothelial cells, MOTS-c increases mitochondrial respiration approximately threefold and ROS production approximately fivefold, which can enhance cellular function but risks ROS-mediated endothelial dysfunction if unregulated. In vascular smooth muscle cells (VSMCs), MDPs such as mitofusin-2-related synthetic peptide (MRSP) instead promote apoptosis via caspase-3 activation and cytochrome c release while inhibiting PI3K/Akt signaling, thereby reducing pathological VSMC proliferation and protecting against neointimal hyperplasia. This differential biology underscores why therapeutic dosing and delivery strategies will require precision.
The authors also note a dual-edged complexity: while MDPs broadly suppress inflammation and oxidative stress, under certain conditions they may paradoxically promote SASP-related secretion of pro-inflammatory cytokines including IL-6 and TNF-α, which can accelerate vascular senescence. This nuance is critical for translational efforts. The review calls for future research to optimize MDP delivery systems, clarify dose-response relationships, and establish whether exogenous MDP administration in human clinical trials can safely recapitulate the vascular protection seen in preclinical models. As biomarkers, MDPs may offer clinically accessible blood-based indicators of vascular aging risk before overt cardiovascular disease manifests.
Key Findings
- Serum MOTS-c levels inversely correlate with coronary artery disease severity, with lower MOTS-c associated with more advanced CAD across clinical studies
- Reduced circulating MOTS-c is positively correlated with impaired reactive hyperemia index (RHI) in obese individuals, linking this peptide directly to endothelial dysfunction
- MOTS-c increases mitochondrial respiration approximately threefold and ROS production approximately fivefold in endothelial cells, producing dual stimulatory and potentially damaging effects
- In vascular smooth muscle cells, MDP analogs promote apoptosis via caspase-3 activation and cytochrome c release while inhibiting PI3K/Akt, reducing pathological neointimal hyperplasia
- Humanin levels rise measurably in response to endurance exercise in athletes, suggesting physical activity upregulates endogenous vascular-protective MDP signaling
- Both humanin and MOTS-c levels decline progressively with age, mirroring the trajectory of vascular functional decline and endothelial senescence
- AMPK activation by MOTS-c mirrors the metabolic effects of exercise — improving insulin sensitivity and metabolic homeostasis — suggesting a pharmacological exercise-mimetic mechanism
Methodology
This is a narrative review article, not a primary study, synthesizing literature retrieved from PubMed, Scopus, and Google Scholar using Boolean search combinations of terms including 'mitochondrial-derived peptides,' 'humanin,' 'MOTS-c,' 'vascular aging,' and 'cardiovascular diseases.' Included studies span January 2000 to October 2024 and encompass animal models, human clinical studies, and cell line experiments. Only peer-reviewed English-language original research articles, systematic reviews, meta-analyses, and reviews were included; editorials, opinion pieces, and conference abstracts without full data were excluded. No formal risk-of-bias assessment or PRISMA protocol is reported, as this is a narrative rather than systematic synthesis.
Study Limitations
As a narrative review rather than a systematic review or meta-analysis, this paper is susceptible to selection bias in the literature cited and does not formally quantify heterogeneity across included studies. Most mechanistic evidence derives from animal and cell-line experiments, with limited large-scale human clinical trial data on MDP supplementation, meaning causality and therapeutic dose ranges in humans remain uncertain. The authors do not declare conflicts of interest in the available text, but the predominantly preclinical evidence base means clinical translation of MDP therapies remains speculative at this stage.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: